1、高致病性禽流感病毒、季节性流感病毒、新冠病毒等重大、突发呼吸道病毒病原学、抗原变异、传播与致病机制研究；

2、新型流感疫苗、新冠疫苗与抗病毒药物药效与机制研究；

3、流感病毒载体、可视化流感报告病毒、流感病毒、冠状病毒等动物感染模型研究。

1、国家自然科学基金面上项目（31970884），基于生物发光报告病毒的新型流感中和抗体检测方法的建立，2020/1-2023/12, 58万元，负责人，在研。

2、国家自然科学基金面上项目，81671640，基于低频同义密码子去优化改造的新型流感减毒活疫苗的研究，2017/1-2020/12，57万元，结题，项目负责人。

3、呼吸疾病国家重点实验室自主开放课题（SKLRD-OP-202209），靶向神经氨酸酶的新型广谱流感疫苗免疫策略研究，2021/1-2023/12, 20万元，负责人，在研。

4、广州市科技计划项目科学研究专项，201606272259269，针对RNA病毒复制的核苷衍生物抑制剂的研究，2017/5-2020/4, 200万元，结题，项目负责人。

5、国家自然科学基金重大研究计划（培育项目），91442102，肺脏巨噬细胞在流感病毒感染后对继发革兰氏阴性细菌感染的作用与机制研究，2015/1- 2017/12，80万元，结题，第一参与人。

6、国家科技重大专项重大新药创制，2014ZX09102044-006，流感中和抗体和创新疫苗研究（H7N9猴血清制备和猴抗体研发），2014/1-2016/12, 290万元，结题，子课题副组长。

7、国家自然科学基金青年基金，31200131，携带荧光素酶的新型可示踪流感病毒及其体内外生物学特性研究，2013/1-2015/12，23万元，结题，项目负责人。

1、Dong J, Dong Z, Feng P, Gao Y, Li J, Wang Y, Han L, Li Z, Wang Q, Niu X, Chufang Li, Weiqi Pan* and Ling Chen*. Influenza Virus Carrying a Codon-Reprogrammed Neuraminidase Gene as a Strategy for Live Attenuated Vaccine. Vaccines, 2023, 11, 391.

2、Runfeng L, Yunlong H, Jicheng H, Weiqi P, Qinhai M, Yongxia S, Chufang L, Jin Z, Zhenhua J, Haiming J, Kui Z, Shuxiang H, Jun D, Xiaobo L, Xiaotao H, Lin W, Nanshan Z, Zifeng Y. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res. 2020,156:104761.

3、Ma Q*, Pan W*, Li R*, Liu B, Li C, Xie Y, Wang Z, Zhao J, Jiang H, Huang J, Shi Y, Dai J, Zheng K, Li X, Yang Z. Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-kappaB signaling pathway. Pharmacol Res. 2020 Aug;158:104850.

4、Yang Wang, Yunhua Lv, Xuefeng Niu, Ji Dong, Pei Feng, Qinming Li, Wei Xu, Jiashun Li, Chufang Li, Jiahui Li, Zhixia Li, Yichu Liu, Yee-Joo Tan, Weiqi Pan*, Ling Chen*. L226Q mutation on influenza H7N9 virus hemagglutinin increases receptor-binding avidity and leads to biased antigenicity evaluation. Journal of Virology, 2020 94 (20): e00667-20.

5、Ji Dong, Peihai Chen, Yang Wang, Yunhua Lv, Ji Xiao, Qinming Li, Zhixia Li, Beiwu Zhang, Xuefeng Niu, Chufang Li, Weiqi Pan*, Ling Chen*. Evaluation of the immune response of a H7N9 candidate vaccine virus derived from the fifth wave A/Guangdong/17SF003/2016. Antiviral Research. 2020, 177, 104776.

6、Xuefeng Niu, Lingzhai Zhao, Linbing Qu, Zhipeng …, Weiqi Pan*, Fuchun Zhang* and Ling Chen*. Convalescent patient-derived monoclonal antibodies targeting different epitopes of E protein confer protection against Zika virus in a neonatal mouse model. Emerg Microbes Infect. 2019; 8(1): 749–759.

7、Pan W, Xie H, Li X, Guan W, Chen P, Zhang B, Zhang M, Dong J, Wang Q, Li Z, Li S, Yang Z, Li C, Zhong N, Huang J, Chen L. Patient-derived avian influenza A (H5N6) virus is highly pathogenic in mice but can be effectively treated by anti-influenza polyclonal antibodies. Emerg Microbes Infect. 2018 Jun 13;7(1):107.

8、Weiqi Pan, Ling Han, Zhenyuan Dong, Xuefeng Niu, Zhengfeng Li, Linlin Bao, Chufang Li, Qinfang Luo, Zifeng Yang, Xiaobo Li, Jicheng Huang, Liqiang Feng, Chuan Qin, Nanshan Zhong, Ling Chen. Induction of neutralizing antibodies to influenza A virus H7N9 by inactivated whole virus in mice and nonhuman primates. Antiviral Research, 2014, 107: 1-5.

9、Weiqi Pan#, Zhenyuan Dong#, Feng Li, Weixu Meng, Liqiang Feng, Xuefeng Niu, Chufang Li, Qinfang Luo, Zhengfeng Li, Caijun Sun, Ling Chen. Visualizing influenza virus infection in living mice. Nature Communications, 2013, 4: 2369.

10. Pan Weiqi, Dong Zhenyuan, Meng Weixu, Zhengwei, Li Ting, Li Chufang, Zhang Beiwu and Chen Ling. Improvement of influenza vaccine strain A/Viernam/1194/2004 (H5N1) growth with the neuraminidase packaging sequence from A/Puerto Rico/8/34. Human vaccines &Immunotherapeutics, 2012, 8 (2):1-8.